Incidence, prevention and treatment of migraine

Maan Alsaaid, Zainab Alowaa, Rawan Abufaia, Rana Rukun, Aisha Saddeek, Mohammed Alnassir, Mohammed Lamfon, Ayah Mohmmed, Njood Bazhair, Afnan AlNouri


Migraine is the second most common type of headache worldwide. It is estimated to affect about one sixth of population. Despite being a primary headache, it is severe, incapacitation, and disturbing normal daily life activity. Therefore, researchers and neuroscientists were and are still endeavouring to understand the basic mechanisms of migraine and its preventive strategies. Treatment of migraine is also a subject of continuous interest. Prevention of migraine is the cornerstone of migraine management. It is achieved by reducing exposure to risk factors, prophylactic treatment of recurrent migraines, and acute treatment prior to exposure to precipitating factors. Treatment of migraine refers to the acute management of headaches when they occur. Many medications are available for abortion or relief of headache, and the choice of which depends on many factors such as the patients' comorbidities, the headache characteristics and severity, the associated symptoms, the adverse events, and the patients' preferences. This article will review and discuss the incidence of migraine, its preventive measures, and treatment updates.



Incidence, Migraine, Prevention, Treatment

Full Text:



Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. Neurology. 2013;81(11):948-55.

Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14(1):1.

Ward TN. Migraine diagnosis and pathophysiology. Contin Lifelong Learn Neurol. 2012;18(4):753-63.

Green MW. Overview of Migraine: Recognition, Diagnosis, and Pathophysiology. Recognition, Diagnosis, and Pathophysiology. In: Headache and Migraine Biology and Management; 2015: 41-49.

Radia C, Rawlence E, Jones S. Migraine management. Clin Pharm. 2015;7(8).

The World Health Organization. Atlas of headache disorders and resources in the world 2011. World Heal Organ. 2011: 72.

Minen MT, Younger DS. Epidemiology of Migraine. Neurol Clin. 2016;34(4):849-61.

Baykan B, Ertas M, Karlı N, Uluduz D, Uygunoglu U, Ekizoglu E, et al. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey. J Headache Pain. 2015;16(1):103.

Academy A. Update: Pharmacological treatment for episodic migraine prevention in adults. Continuum (Minneap Minn). 2015;21(4):1165-6.

Rizzoli PB. Acute and preventive treatment of migraine. Continuum (Minneap Minn). 2012;18(4):764-82.

Lampl C. Migraine-diagnostic features, acute therapy and prophylactics. Ther Umsch. 2011;68(9):501-5.

Moschiano F, D’Amico D, Bussone G. Migraine prophylaxis: Key points for the practising clinician. Neurol Sci. 2009;30(Suppl. 1).

Bulboacǎ AE, Bolboacǎ SD, Stǎnescu IC, Sfrângeu CA, Bulboacǎ AC. Preemptive analgesic and antioxidative effect of curcumin for experimental migraine. Biomed Res Int. 2017: 2017.

Taylor FR. Menstrual migraine. Headache. 2011;51(4):624-5.

Davis C, Reno E, Maa E, Roach R. History of Migraine Predicts Headache at High Altitude. High Alt Med Biol. 2016;17(4):300-4.

Rao PM, Ailani J. Diagnosis and treatment of migraine. J Clin Outcomes Manag. 2017;24(11).

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults report of the quality standards subcommittee of the American academy of neurology and the american headache society. Neurology. 2012;78(17):1337-45.

Dodick DW. Prevention of migraine. BMJ. 2010;341(7776):740.

Magyar M, Csepany E, Gyure T, Bozsik G, Bereczki D, Ertsey C. Tricyclic antidepressant therapy in headache. Neuropsychopharmacol Hung. 2015;17(4):177-82.

Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs. 2010;24(1):21-33.

Shimizu T. Beta blockers in migraine prophylaxis. Brain Nerve. 2009;61(10):1125-30.

Ramadan NM. Current trends in migraine prophylaxis. In: Headache. 2007;47.

Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type a to identify the trigger sites. Plast Reconstr Surg. 2012;129(2):413-9.

Magis D. Neuromodulation in migraine: State of the art and perspectives. Expert Rev Med Devices. 2015;12(3):329-39.

Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn). 2015;21(4):953-72.

Hsu Y-C, Lin K-C, Taiwan Headache Society TGSOTHS. Medical Treatment Guidelines for Acute Migraine Attacks. Acta Neurol Taiwan. 2017;26(2):78-96.

Gong L, Li X, Yang XD. Meta-analysis of curative effect of Metoclopramide on treating migraine. J Clin Neurol. 2012;25(2):92-5.

Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.

Joshi S, Rapoport AM. Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: Clinical evidence and practical experience. Ther Adv Neurol Disord. 2017;10(4):217-26.

Loder E. Triptan Therapy in Migraine. N Engl J Med. 2010;363(1):63-70.

Fischer M, Frank F, Wille G, Brössner G, Klien SK, Lackner P. 20 years of triptan use in Austria. Cephalalgia. 2015;35(6):28.

Lenaerts MEP, Couch JR. Treatment of Headache Following Triptan Failure After Successful Triptan Therapy. Curr Treat Options Neurol. 2015;17(6):1-7.

Moore J. Dihydroergotamine. In: XPharm: The Comprehensive Pharmacology Reference; 2011:1-5.